Evolve Biologics, Inc.

There were several significant leadership changes across the biopharma and life sciences industries, with Homology Medicines and MiMedx posting new CEOs in the year's second half. Homology Medicines – Albert Seymour was named president and chief executive officer. He succeeds Arthur Tzianabos, appointed chairperson of the board of directors. Tzianabos and Dr. Seymour joined Homology in 2016 as CEO and chief scientific officer, respectively. Before Homology, Seymour was the senior vice president and head of global research and nonclinical development at Shire plc. Prior to that, he spent 14 years at Pfizer. GlycoMimetics Inc. – Edwin Rock was appointed chief medical officer. He most recently served as CMO for Partner Therapeutics, privately-held commercial-stage biotech based in Massachusetts. Before that, he served as head of clinical research at Macrogenics. He previously served in clinical development leadership roles at Astex Pharmaceuticals, Otsuka, and GSK, leading clinical trial programs for drug candidates across hematology and oncology. Early in his career, he was a medical officer in oncology drug review at the FDA. Evolve Biologics – Chris Carr was named chief financial officer and will be responsible for all finance and accounting functions. He previously served as CFO of Aeon Biopharma and, before that, was head of finance and IT at Dendreon Pharmaceuticals. He also held financial management positions with Abbott Laboratories, PerkinElmer, and the Genzyme Corporation. MiMedx Group – K. Todd Newton, a member of the company board of directors, has been appointed interim CEO. He replaced Timothy R. Wright, who served as MiMedx's CEO since May of 2019. The Board has appointed a special committee to direct the search for a new CEO. Instil Bio, Inc. – Texas-based Instil tapped Tim Moore for the role of chief operating officer. Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations, including at Genentech, Kite and most recently, PACT Pharma, where he was president and COO. Before joining PACT, he served as head of technical operations at Kite, a Gilead Sciences company. Before Kite, he was head of global technical operations for biologics at Genentech. hC Biosciences, Inc. – Based in Cambridge, Mass., hC Biosciences named Yosef Landesman as CSO and Gautam Goel as chief data science officer. Landesman previously served as senior vice president of research and translational medicine at Karyopharm Therapeutics. Before that, he was at Alnylam Pharmaceuticals. Goel most recently helmed an inter-disciplinary R&D/consulting practice. Prior to this position, Goel was director of precision medicine at ImmusanT. IBRI – The Indiana Biosciences Research Institute named Michele Sawyer as its new CFO. Most recently, Sawyer served as the executive director/general auditor of corporate audit services at Elanco Animal Health, a division of Eli Lilly. Before that, she was COO of the nutritional health business unit with Elanco. During her 18 years at Eli Lilly & Company, Sawyer served in many leadership roles, including controller of Lilly Research Lab's Development Center of Excellence. Zenas BioPharma – Simon Lowry was named CMO of the Sino-American Zenas. Prior to joining Zenas, Lowry was CMO at Kinevant Science, a clinical-stage biopharmaceutical company focused on treating rare inflammatory and autoimmune diseases. Lowry was previously head of immunology R&D at Roivant Sciences. He also served as CMO at Sun Pharma North America. Early in his career, he worked at Novartis, where he served as vice president of global medical affairs franchise head of immunology & dermatology. He also held multiple leadership roles at Pfizer. Nitrase Therapeutics – Arun K. Kashyap was appointed to the newly-created role of senior vice president of oncology. Kashyap was previously the vice president of research at Arch Oncology, where he directed the strategy and operations of discovery and preclinical drug development. At Dren Bio, Kashyap was a senior member of the founding scientific team responsible for leading the research department in discovering and validating antibody targets. He served in a similar capacity at Compugen. High Q Technologies – Life sciences tool manufacturer High Q named Andrew Wiles as vice president of R&D. Before High Q, Wiles was director of R&D at NDI, overseeing new product development, early-stage technology research, and sustaining engineering for in-market products. Garuda Therapeutics – Roger Sawhney was named CFO of Garuda. Prior to joining the company, he served as both CFO and chief business officer of Omega Therapeutics. Before Omega, Sawhney served in various roles, including partner at Bain Capital and Boston Consulting Group. He was also a Director at KKR in health care private equity and growth equity investing and senior vice president and global head of corporate strategy at Novartis. Ocugen, Inc. – Pennsylvania-based Ocugen tapped Robert J. Hopkins as chief medical officer. Also, Arun Upadhyay, who served as SVP of R&D, was named CSO. Hopkins has held senior level positions at Merck Research Labs, DynPort Vaccine Company, Emergent BioSolutions, and Aeras. Before joining Ocugen, he was the CMO at Adaptive Phage Therapeutics, overseeing regulatory affairs, clinical development, and clinical operations. Before joining Ocugen, Upadhyay led ophthalmic drug development and delivery research at the University of Colorado Denver in the Department of Pharmaceutical Sciences. Merck – George Addona was named SVP and head of discovery, preclinical and translational medicine at Merck Research Laboratories. Addona will oversee the early-stage pipeline, early human studies and biomarker development. Since joining Merck in 2008, Addona has held positions of increasing responsibility across the company's pharmacology organization. Most recently, he was VP of quantitative biosciences. Before leading QB, Addona directed company teams in Boston, Singapore and South San Francisco. Prior to joining Merck, Addona held roles of increasing responsibility at Novartis and Praecis Pharmaceuticals. Sanford Burnham Prebys – David Brenner was appointed to serve as the institute's next president and CEO. Brenner joins Sanford Burnham Prebys following more than 15 years as vice chancellor for Health Sciences at UC San Diego. He will assume his new role effective Sept. 14. Exscientia Ltd. – Caroline Rowland was named chief people officer of Exscientia, a newly-created role for the U.K.-based AI company. Prior to joining the company, she served as the VP of talent at Arm, a leading technology company in the U.K. and the world's largest provider of semiconductors. She also held roles with Diageo and Deloitte. Longhorn Vaccines and Diagnostics – Zoe Silver was named SVP of genomics and diagnostics. He most recently served as SVP of genomics and diagnostics at SiO2 with similar roles in marketing at Tecan and BSN Medical and in marketing leadership roles at White Hot Pizza and Ben & Jerry's.

HAUPPAUGE, NY / ACCESSWIRE / July 19, 2022 / Emergent Health Corp. ("Emergent") (OTC PINK:EMGE) announces it has executed a Letter of Intent to acquire Evolutionary Biologics, Inc., (website: Evolutionary Biologics), a new kind of biologics company founded for a clear purpose: to bring cutting edge regenerative products to the medical community. The final purchase price, to be negotiated by the Parties, will include the issuance of equity in Emergent and a defined capital investment into Evolutionary Biologics for sales, scaling of the company operations and promotions, all to be based on projections, and subject to funding, as negotiated and agreed to between Emergent and Evolutionary. Evolutionary Biologics products include Evo Hybrid and HydrEyes. Evo Hybrid helps to jumpstart your body's own natural healing power to help bring your skin back to youthful suppleness. HydrEyes helps to reduce redness to help reveal your eyes' natural radiance. Evolutionary Biologics' goal is to create consumer awareness of regenerative medicine with a global presence using science and technology to build products to create external beauty. Evolutionary Biologics intends to use push and pull marketing, social media, and consumer awareness events to create collaborations with clinics for its products. Upon the completion of this transaction and the previously announced letters of intent to acquire Fusion Specialty Pharmacies, nationally accredited compounding pharmacies licensed in 27 states and located in St. George, Utah dedicated to formulating creative, individualized, and compounded medications that can improve compliance, maximize the potential for therapeutic success, and reduce the overall cost of healthcare ("Fusion") and Regen Biowellness, a distributor of various products in the plant-based and regenerative medical fields, former L'Oréal President Jim Morrison has agreed to be appointed CEO of Emergent on a full time basis. Jim Morrison, President/CEO of Evolutionary Biologics, stated, "The marriage between Emergent Health and Evolutionary Biologics will allow both companies to further their respective businesses in the new age medical industry. It also establishes Emergent Health as a leading company for plant-based wellness and regenerative health." James W. Zimbler, CEO of Emergent stated, "With the planned advent and addition of Evolutionary Biologics to Emergent Health, it takes our goals and plans of regenerative care to a new level and furthers our plans to make Emergent Health a premier health and wellness company, giving Emergent another avenue to reach the consumer." ABOUT EMERGENT HEALTH CORPORATION Emergent Health Corp. is developing a product line in the fields of Regenerative Medicine and improved neutraceuticals and phytonutritionals available to the general public without a prescription. Its products are comprised of ingestibles as well as topicals for the whole family. The company distributes its products online and through content-based shopping using Influencers to position products in their produced content throughout the United States and Internationally. PharmaZu, its newly acquired subsidiary, is a pure play, e-commerce products and service provider focused on the pet community, pet pharmacy and wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure, or prevent any disease. Before using any products, you should always consult with your Veterinarian and Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: James Zimbler, CEO jzimbler@emergenthealthcompany.com 631-806-1420 SOURCE: Emergent Health Corp. View source version on accesswire.com:

Russia-based R-Pharm Group announced a new rheumatoid arthritis (RA) drug, olokizumab, has been found to offer significant benefits to patients. Findings from the Phase III CREDO study were presented at the British Society of Rheumatology Annual Conference. The results showed significant improvements to the signs and symptoms of RA patients compared to those in the placebo and methotrexate group, not only in biologically naïve patients, but also among the difficult to treat population with active RA inadequately controlled by TNF-α inhibitor therapy, the company announced. Olokizumab is a monoclonal antibody specific for the interleukin-6 (IL-6) cytokine. It targets the IL-6 ligand rather than the receptor, and selectively blocks the final assembly of the signaling complex, the company announced. Olokizumab is the first direct inhibitor of interleukin-6 (IL-6) authorized for commercial use for this indication. Treatment with olokizumab was well-tolerated and consistent with the established safety profile of anti-IL-6 agents, the company announced. In May 2020, olokizumab received a market authorization from Russia’s Ministry of Health under the trade name "Artlegia." R-Pharm is currently establishing GMP-certified olokizumab production at facilities in France and Germany to enable prompt approval of the drug in the American and European markets. Elsewhere around the globe: IcanoMAB – Germany-based IcanoMAB received positive regulatory advice for the clinical development path of its anti-IL-1R7 antibody in late-stage COVID-19. IcanoMAB has published the pre-clinical proof-of-concept for the anti-IL-1R7 antibody that blocks the signal transduction of the interleukin-18 (IL-18) receptor. Recently, the company secured positive regulatory advice for its clinical development plan in late-stage COVID-19. IcanoMAB is currently entering discussions with interested parties for a development partnership of its anti IL-1R7 antagonist antibody. Memo Therapeutics – Switzerland’s Memo Therapeutics announced its COVID-19 antibody MTX-COVAB has shown efficacy against both the original virus as well as the UK variant (B.1.1.7). Memo is now preparing MTX-COVAB for clinical evaluation. Using its microfluidic, single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery, Memo can discover novel antibodies at unprecedented speed, efficiency and sensitivity derived from recovered patient samples. This approach has enabled the company to also identify a very promising antibody candidate against the South African variant (B.1.351). Sphere Fluidics – U.K.-based Sphere Fluidics, which develops single cell analysis systems, announced it has enhanced the capability and performance of its Cyto-Mine System. The updated design provides improvements that will help streamline workflows, reduce costs, increase throughput, and enable high-value clones to be captured in a single run, the company said. Cyto-Mine is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. The new electronics design improves system performance, reliability, and stability, while the updated software features help to provide a better user experience, reduce user-instrument interaction, and allow for more robust data analysis. Holborn – Also based in the U.K., AI Solutions company Holborn will launch a dedicated business unit in India dubbed Holborn Wells India. Holborn said the launch is in response to an increasing need for “high-quality and cost-effective molecular In Vitro Diagnostics (IVD) in the country due to ongoing COVID-19 concerns.” Holborn Wells India will develop and deliver IVD products for infectious diseases by leveraging data and innovative diagnostic capabilities, with continued pressure on the nation’s health service as a result of the pandemic accelerating the need for operational capacity. Holborn Wells India already signed a deal with an Indian-based company to produce Holborn Wells’ IVD products in order to assist until a fully operational manufacturing location can be established. Milestone Pharmaceuticals – Canada’s Milestone Pharmaceuticals Inc. announced an exclusive license and collaboration with Shanghai-based Ji Xing Pharmaceuticals. The companies will develop and commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) and additional cardiovascular conditions in Greater China. Under terms of the deal, Milestone will receive an upfront cash payment consisting of $15 million and a $5 million equity investment. In addition, Milestone is eligible to receive up to $107.5 million in milestone payments and royalties on future sales of etripamil in Greater China. BioMed X – Germany’s BioMed X extended its collaboration agreement with Merck. Under terms of the new agreement, Merck will start up to six additional research projects at the BioMed X Institute, building on ongoing research projects in the fields of oncology and autoimmunity. The next joint global crowdsourcing project will explore mechanisms of immune senescence and mitochondrial dysfunction in regulatory T cells and other T cell subsets that are shared in human autoimmunity and aging, BioMed X announced. Evolve Biologics – Canada-based Evolve Biologics Inc. selected DPR Construction to act as the General Contractor for construction of its new state-of-the-art commercial facility to be built in Texas. The new facility will produce plasma-derived therapeutics, initially Intravenous Immunoglobulin (IVIG) and Human Serum Albumin (HSA), using Evolve’s innovative and proprietary technology, PlasmaCap EBA. The company expects to break ground this summer. Owlstone Medical – Breath biopsy company Owlstone, based in the U.K., announced agreements with Functional Gut Clinic (FGC) and Functional Gut Diagnostics (FGD), leading providers of smart solutions for the diagnosis of gut health problems. The partnership will combine Owlstone’s expertise in breath-based testing with FGC and FGD’s leadership in digestive health, to strengthen the provision of efficient and high-quality at-home breath testing through a UK Lab Services Agreement and accelerate development of future breath tests in digestive health through a Collaboration Agreement. BD -- BD (Becton, Dickinson and Company) will build a €165 million ($200 million USD) high-tech manufacturing facility in Spain. When operational, the company said the site will employ up to 600 jobs by 2030. Construction is expected to begin later this year. The site will initially have a workforce of 150 people and encompass an area of 86,000 square feet. When fully operational in 2030, the facility will have an area of 323,000 square feet. Galapagos NV – Belgium-based Galapagos announced that the first patient has been enrolled in the FILOSOPHY Phase 4 European real-world outcomes study. The goal of the FILOSOPHY study is to advance understanding of the effectiveness and safety of filgotinib as it is used with patients with rheumatoid arthritis (RA) in clinical practice. Basilea Pharmaceutica International – Switzerland-based Basilea was awarded $2.7 million from CARB-X to develop a novel class of antibiotics to treat Gram-negative bacterial infections. Gram-negative bacteria, often called ‘superbugs’ because they have developed resistance at an alarming pace to existing antibiotics, kill an estimated 700,000 people each year around the world.